The label is European and the burden is not. Bavarian Nordic’s own chief executive names the gap in his quote: children have carried a disproportionate share of recent mpox outbreaks, particularly in parts of Africa, where paediatric cases have driven the emergency. A type II variation in Brussels does nothing directly for a child in Kinshasa. What it does is indirect, and it is the entire reason this decision matters. A stringent regulatory authority label is the document the rest of the system is built on.

• This approval is procurement infrastructure, not clinical news. A label from a stringent regulatory authority is the reference that underpins World Health Organization listing, and WHO listing is what lets UNICEF, Gavi and national immunisation programmes buy at scale. It is also the dossier that regulators in low and middle income countries lean on through reliance pathways rather than repeating a review they have neither the capacity nor the reason to run twice. So judge this by how fast the paediatric indication propagates into those channels, not by uptake in Europe, where paediatric mpox is close to absent.
• CEPI paid for the trial, and that is the structural story. An immunobridging study in 227 children serves a population with almost no commercial value to a European vaccine maker, which is exactly why it required public health money to exist at all. Read that in reverse and the implication is uncomfortable: without CEPI this label does not happen, and the children carrying the outbreak remain off-label. Anyone tracking access in outbreak diseases should be watching who funds paediatric extensions, because that funding decision settles the label years before a regulator ever sees a dossier.
• Be precise about what the evidence shows. This is immunobridging, 227 children measured against 224 adults, reporting non-inferior immune responses and comparable safety. There is no efficacy endpoint in children and there was never going to be one, because a placebo-controlled efficacy trial in children during an outbreak is neither feasible nor defensible. That is the right trade, but it should be stated rather than glossed. The paediatric label rests on immune response, and genuine protection in children will be established, if at all, through effectiveness data gathered after deployment. The number to demand is post-deployment effectiveness from the African programmes, not the immunogenicity ratio.